Close
Novotech
Jabsco PureFlo 21 Single Use

LabCorps drug development business, Covance Acquired of GlobalCare Clinical Trials, LLC

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Overqualified and Underutilized: The Hidden Risk in Physician Hiring

Hospitals brag about “top talent,” then act stunned when...

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Biopharma companies are continuing to redirect production strategies toward...

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...
- Advertisement -

LabCorp’s drug development business, Covance, has acquired GlobalCare, a provider of patient-centric decentralized clinical trials support services.

This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. Covance will leverage GlobalCare’s mobile healthcare services, site staffing support, patient transport assistance and contracted central pharmacy services.

GlobalCare’s customers will have access to resources and technology to scale services to meet growing industry needs. GlobalCare will also complement its existing services with additional important decentralized clinical trial services via Covance capabilities such as eConsent, tele-health, Electronic Data Capture (EDC), online patient scheduling, connected device solutions, and more. This transaction allows for seamless integration of a full suite of biopharmaceutical services.

In November 2019, Covance launched its Decentralized Clinical Trials (DCT) services, which integrate capabilities from across the company’s diagnostic and drug development business units, to improve patient experience and increase participation.

Latest stories

Related stories

Overqualified and Underutilized: The Hidden Risk in Physician Hiring

Hospitals brag about “top talent,” then act stunned when...

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Biopharma companies are continuing to redirect production strategies toward...

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »